Trial Profile
INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Acronyms INVICTUS-ASA
- 14 Jul 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Mar 2021 Planned End Date changed from 1 Oct 2021 to 1 Aug 2022.
- 03 Mar 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Apr 2022.